Sensus Healthcare (SRTS) Set to Post Earnings on Thursday

Key Points

• Sensus Healthcare is expected to report Q3 2026 results after market close on November 12, with analysts forecasting a loss of $0.055 per share and revenue of $6.61 million.
• In its prior quarter, the company reported a loss of $0.53 per share, missing estimates, and revenue of $2.29 million versus expectations of $4.60 million.
• Insiders bought 120,171 shares over the past 90 days. Analysts’ consensus rating is “Moderate Buy,” with a target price of $5.83.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Sensus Healthcare to announce earnings of ($0.0550) per share and revenue of $6.61 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The business had revenue of $2.29 million during the quarter, compared to analysts' expectations of $4.60 million.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $3.25 on Thursday. The firm has a fifty day moving average price of $3.02 and a 200 day moving average price of $3.52. Sensus Healthcare has a 1 year low of $2.66 and a 1 year high of $5.49.

Insider Buying and Selling at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta purchased 37,537 shares of Sensus Healthcare stock in a transaction that occurred on Friday, August 28th. The stock was bought at an average price of $3.44 per share, with a total value of $129,127.28. Following the acquisition, the director owned 267,480 shares of the company's stock, valued at $920,131.20. This trade represents a 16.32% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders bought 120,171 shares of company stock valued at $405,230. 10.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SRTS. Lake Street Capital lowered their target price on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Alliance Global Partners restated a "buy" rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare has an average rating of "Moderate Buy" and a consensus target price of $5.83.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.

Founded in 2010, Sensus Healthcare is headquartered in Boca Raton, Florida.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.